Less than one in 10 individuals that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the World Health Organization as it issues its initial recommendations on the therapies.
With in excess of 1,000,000,000 individuals worldwide now obese, it is urging broader and more equitable access to these injectable treatments.
Per forecasts, over two billion will be obese by 2030 unless action is taken.
"Our latest guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are major hurdles to widespread access to the jabs that can assist patients in reducing considerable body mass, notes the body.
Weight-Loss Drug Shortage
Despite the present most favorable outlook, the supply of GLP-1 therapies could only cover about 100 million people – less than 10% of eligible patients, according to the health organization.
The guideline urges countries and companies to widen availability, via strategies including patent sharing.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Weight-Loss Injections Function
These medications replicate a body's own hormone to delay gastric emptying, curb appetite and increase the sense of being full so users eat less.
Individuals typically start to lose weight within a few weeks of beginning the weekly injections.
Evidence points to people may see weight return a year later of stopping the treatment, when their typical hunger come back.
To be above a healthy weight raises your risk for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity concerns people in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.
